Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Minority Interest: 2010-2025

Historic Minority Interest for Arrowhead Pharmaceuticals (ARWR) over the last 14 years, with Sep 2025 value amounting to $37.4 million.

  • Arrowhead Pharmaceuticals' Minority Interest rose 564.96% to $37.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.4 million, marking a year-over-year increase of 564.96%. This contributed to the annual value of $37.4 million for FY2025, which is 564.96% up from last year.
  • Latest data reveals that Arrowhead Pharmaceuticals reported Minority Interest of $37.4 million as of FY2025, which was up 564.96% from $5.6 million recorded in FY2024.
  • In the past 5 years, Arrowhead Pharmaceuticals' Minority Interest registered a high of $37.4 million during FY2025, and its lowest value of $5.6 million during FY2024.
  • For the 3-year period, Arrowhead Pharmaceuticals' Minority Interest averaged around $19.6 million, with its median value being $15.8 million (2023).
  • Its Minority Interest has fluctuated over the past 5 years, first crashed by 64.48% in 2024, then skyrocketed by 564.96% in 2025.
  • Arrowhead Pharmaceuticals' Minority Interest (Yearly) stood at $19.8 million in 2022, then declined by 20.18% to $15.8 million in 2023, then tumbled by 64.48% to $5.6 million in 2024, then soared by 564.96% to $37.4 million in 2025.